EvoRx strives to discover and develop innovative peptide therapeutic and targeted radiopharmaceuticals for treatment and diagnosis of disease with high unmet medical need. It’s proprietary Evo-Link™ technology rapidly generates exceedingly high diversity cyclic peptide libraries. The libraries are screened for drug-like activity in environments that mimic the physiological environment of the body. This results in EvoTides™, uniquely structured peptides that are highly stable in human serum, have antibody-like specificity and affinity, and can be designed to be membrane permeable. These features allow us to target protein interactions previously thought of as “undruggable.”